Amaryl (glimepiride)
October 26, 2004
Audience: Neuropsychiatric healthcare professionals and pharmacists
[October 26, 2004] FDA, Janssen Pharmaceutica Products, and Johnson & Johnson Pharmaceutical Research & Development notified healthcare professionals of reports of medication errors involving confusion between Reminyl, a drug approved for the treatment of mild to moderate dementia of the Alzheimer's type, and Amaryl (glimepiride), a product of Aventis Pharmaceuticals, indicated for the treatment of non-insulin dependent (Type 2) diabetes mellitus. These reports include instances in which Reminyl was prescribed but Amaryl was incorrectly dispensed and administered instead, leading to various adverse events including severe hypoglycemia and one death.[UPDATE 12/23/2004] Letter to Pharmacists from Aventis Pharmaceuticals posted.
[October 15, 2004 - Letter to Healthcare Professionals - Janssen]
[October 19, 2004 - Letter to Pharmacists - Janssen] PDF Format
[November 5, 2004 - Letter to Pharmacists - Aventis] PDF Format
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.